Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.52 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.48 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.45 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.44 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.44 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.44 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.44 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.44 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.44 |
| ▸ | POLA1 known ✓ | P09884 | 1/20 | 0.43 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502263 | 0.97 | MAPT (0.55) | MAPTNPC1KDM4ERAB9AIDO1 | |
| SCHEMBL833283 | 0.97 | MAPT (0.55) | MAPTNPC1KDM4ERAB9AIDO1 | |
| SCHEMBL9717151 | 0.80 | MAPT (0.48) | MAPTNPC1KDM4ERAB9AIDO1 | |
| Hydrochloric Acid SCHEMBL897927 | 0.79 | RAPGEF4 (0.53) | MAPTNPC1KDM4ERAB9APOLB | |
| Hydrochloric Acid SCHEMBL4206989 | 0.79 | CA2 (0.50) | MAPTNPC1KDM4ERAB9AIDO1 | |
| Hydrochloric Acid SCHEMBL25252460 | 0.79 | MEN1 (0.55) | MAPTNPC1KDM4ERAB9AIDO1 | |
| Hydrochloric Acid SCHEMBL1160446 | 0.79 | MEN1 (0.55) | MAPTNPC1KDM4ERAB9AIDO1 | |
| Hydrochloric Acid SCHEMBL4052903 | 0.79 | MAPT (0.50) | MAPTNPC1KDM4ERAB9AIDO1 | |
| Hydrochloric Acid SCHEMBL29418041 | 0.79 | RAPGEF4 (0.49) | MAPTNPC1KDM4ERAB9AIDO1 | |
| Hydrochloric Acid SCHEMBL2171244 | 0.79 | RAPGEF4 (0.49) | MAPTNPC1KDM4ERAB9AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025020685-A1 | PEROVSKITE THIN FILM LAYER AND PREPARATION METHOD THEREFOR, AND PEROVSKITE SILICON STACKED SOLAR CELL AND PREPARATION METHOD THEREFOR | 通威太阳能（成都）有限公司 | 2025-01-30 | — | — | WO | claimed |
| CN-110117256-B | Synthesis method of bixafen | 芮城县斯普伦迪生物工程有限公司 | 2023-06-30 | — | — | CN | claimed |
| EP-0918052-B1 | Improved polymeric mdi color | BAYER AG (US) | 2003-05-28 | — | — | EP | claimed |
| US-5942151-A | PREVENTING THE DISCOLORATION OF PRODUCING POLYMETHYLENEPOLYPHENYLENE POLYISOCYANATE BY ADDING AN ADDITIVE HYDRAZINE OR A HYDRAZINE DERIVATIVE | BAYER CORPORATION (US) | 1999-08-24 | — | — | US | claimed |
| EP-0918052-A1 | Improved polymeric mdi color | Bayer Corporation (US) | 1999-05-26 | — | — | EP | claimed |
| CN-119552120-A | Pyrazole and imidazole compounds for inhibiting IL-17 and rory | 里亚塔医药公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2025020685-A1 | PEROVSKITE THIN FILM LAYER AND PREPARATION METHOD THEREFOR, AND PEROVSKITE SILICON STACKED SOLAR CELL AND PREPARATION METHOD THEREFOR | 通威太阳能（成都）有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-112654610-B | Pyrazole and imidazole compounds for inhibiting IL-17 and rory | 里亚塔医药公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20240360084-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS INC (US) | 2024-10-31 | — | — | US | disclosed |
| CN-118724727-A | Preparation method of 3',4' -dichloro-5-fluoro-2-benzidine | 江苏七洲绿色科技研究院有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240217934-A1 | FLUORINE-CONTAINING PYRAZOLE COMPOUND AND PRODUCTION METHOD THEREFOR | UNIMATEC CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| CN-116003322-B | Pyrazole ether compound as well as preparation method and application thereof | 南通泰禾化工股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-4447442-A | ANTIINFLAMMATORY, ANTIARTHRITIC, ANTIHISTAMINE, ANTIALLERGENS, ANALGESICS, BACTERICIDES, AND FUNGICIDES | AMERICAN CYANAMID COMPANY (US) | 1984-05-08 | — | — | US | disclosed |
| EP-0070376-A1 | Heterocyclic substituted-amino-pyrazolines | AMERICAN CYANAMID COMPANY (US) | 1983-01-26 | — | — | EP | disclosed |
| US-4348527-A | ANALGESICS, BACTERICIDES, FUNGICIDES | AMERICAN CYANAMID COMPANY (US) | 1982-09-07 | — | — | US | disclosed |
| US-4302589-A | ANTIPSYCHOTIC | AMERICAN CYANAMID COMPANY (US) | 1981-11-24 | — | — | US | disclosed |
| US-4255442-A | 2-[(Methylsulfinyl)]-3-phenylindoles | SCHERING CORPORATION (US) | 1981-03-10 | — | — | US | disclosed |
| US-4226773-A | Pyrazolyl amino imidazolines as diuretic agents | ABBOTT LABORATORIES (US) | 1980-10-07 | — | — | US | disclosed |
| US-4207317-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-06-10 | — | — | US | disclosed |
| EP-0000972-A2 | 2-Substituted-3-phenylindoles, their preparation, and pharmaceutical compositions containing them | Technobiotic Ltd. (CH) | 1979-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217934-A1 | FLUORINE-CONTAINING PYRAZOLE COMPOUND AND PRODUCTION METHOD THEREFOR | CYP2F1, CYP4F11, CYP51A1 | GAA 3223/4885GLA 2653/4885CA2 4504/4885 |
| US-20240360084-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | RORC, RORB, RORA | GAA 2350/4885GLA 1886/4885CA2 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.